Simulations Plus – Consensus Indicates Potential 21.3% Upside

Broker Ratings

Simulations Plus with ticker code (SLP) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 95 and 76 calculating the mean target price we have 82.75. Now with the previous closing price of 68.2 this now indicates there is a potential upside of 21.3%. The 50 day MA is 62.47 and the 200 day MA is 63.58. The market capitalisation for the company is $1,459m. You can visit the company’s website by visiting: http://www.simulations-plus.com

The potential market cap would be $1,771m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Simulations Plus develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.

Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:

    Twitter
    LinkedIn
    Facebook
    Email
    Reddit

      AIM All Share Index